Company: LNAI
Filing Date: 2025-12-03
Form Type: 424B5
Source: 0001731122-25-001626
Chunk: 37

Company: Lunai Bioworks Inc.
Filing Date: 2025-12-03
Form: 424B5
Chunk 37
---
or clinical trials. Specifically, Renovaro Cube is focused on developing products and services aimed at (i) early cancer characterization,
(ii) personalized treatment selection, (iii) prediction and tracking response to therapies, (iv) recurrence detection and efficacy monitoring,
and (v) ultimately, drug discovery.

Renovaro Cube was initially incorporated
as Grace Systems B.V. (“Grace Systems”) in 2013 under the laws of the Netherlands to develop unique data mining algorithms
to enable banking, finance and government entities to extract business insights from data. Grace Systems began applying its algorithms
to biological data in 2018 to uncover cancer-associated patterns. Beginning in 2018, Grace Systems pivoted its platform to focus only
on healthcare. Renovaro Cube has focused on developing its AI technology for early cancer detection.

Renovaro Cube has now focused
on commercialization of its AI technology. Renovaro Cube believes that it has developed a unique approach to the early detection and diagnosis
of cancer and its recurrence and, in time, other rare diseases through the systematic analysis of data using AI technologies, data mining
procedures and algorithms for health technology.

Renovaro Cube’s technology
has been trained on complex heterogeneous cancer data and appears to find patterns associated with cancer in public and private data resources.
With the help of Renovaro Cube’s algorithms, discovered patterns may be translated into biomarkers that can be used in a clinical
setting to target various aspects of cancer diagnosis and treatment.

<div align='center'>3</div>

Renovaro Cube’s Strategy

Renovaro Cube’s product development
focuses on four core areas:

| ● | Early Detection. Multi-cancer                                                                                                             
 early detection (“MCED”) blood tests are advanced diagnostic tools that analyze cell-derived molecules present in the                     
 bloodstream. These tests specifically look for abnormal genetic, epigenetic or proteomic patterns of these cell-derived molecules,        
 which can indicate the presence of cancer cells. By examining the molecules shed from various cells, including cancer cells, MCED         
 tests aim to detect cancer at an early stage. This approach holds promise for improving cancer detection and potentially saving lives.    |
| ● | Recurrence of cancer.                                                                                                                     
 A recurrence refers to the return of cancer after a period of remission. A cancer recurrence happens because, in spite of the efforts     
 to kill the cancer, some cells may remain, which grow and eventually cause symptoms. In rare instances, a patient may develop a new       
 cancer that’s completely unrelated to